Atlas Trials

Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer

Clinical trial NCT02630199 · COMPLETED

Trial details

NCT number
NCT02630199
Sponsor
Samsung Medical Center
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Refractory Cancer
Start date
2015-12-01
Primary completion
2020-12-01
Enrollment
65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.